We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Eli Lilly (LLY) Stock Sinks As Market Gains: What You Should Know
Read MoreHide Full Article
In the latest trading session, Eli Lilly (LLY - Free Report) closed at $271.73, marking a -1.63% move from the previous day. This change lagged the S&P 500's daily gain of 0.64%. At the same time, the Dow added 0.68%, and the tech-heavy Nasdaq gained 0.46%.
Coming into today, shares of the drugmaker had gained 12.48% in the past month. In that same time, the Medical sector gained 5.28%, while the S&P 500 gained 4.56%.
Wall Street will be looking for positivity from Eli Lilly as it approaches its next earnings report date. On that day, Eli Lilly is projected to report earnings of $1.99 per share, which would represent a year-over-year decline of 27.64%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $7.56 billion, up 1.61% from the year-ago period.
Any recent changes to analyst estimates for Eli Lilly should also be noted by investors. Recent revisions tend to reflect the latest near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 1.79% higher within the past month. Eli Lilly is currently sporting a Zacks Rank of #3 (Hold).
Looking at its valuation, Eli Lilly is holding a Forward P/E ratio of 33.78. Its industry sports an average Forward P/E of 13.91, so we one might conclude that Eli Lilly is trading at a premium comparatively.
It is also worth noting that LLY currently has a PEG ratio of 2.12. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The Large Cap Pharmaceuticals industry currently had an average PEG ratio of 2.11 as of yesterday's close.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 167, which puts it in the bottom 35% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
View the Zacks #1 Rank List
Image: Bigstock
Eli Lilly (LLY) Stock Sinks As Market Gains: What You Should Know
In the latest trading session, Eli Lilly (LLY - Free Report) closed at $271.73, marking a -1.63% move from the previous day. This change lagged the S&P 500's daily gain of 0.64%. At the same time, the Dow added 0.68%, and the tech-heavy Nasdaq gained 0.46%.
Coming into today, shares of the drugmaker had gained 12.48% in the past month. In that same time, the Medical sector gained 5.28%, while the S&P 500 gained 4.56%.
Wall Street will be looking for positivity from Eli Lilly as it approaches its next earnings report date. On that day, Eli Lilly is projected to report earnings of $1.99 per share, which would represent a year-over-year decline of 27.64%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $7.56 billion, up 1.61% from the year-ago period.
Any recent changes to analyst estimates for Eli Lilly should also be noted by investors. Recent revisions tend to reflect the latest near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 1.79% higher within the past month. Eli Lilly is currently sporting a Zacks Rank of #3 (Hold).
Looking at its valuation, Eli Lilly is holding a Forward P/E ratio of 33.78. Its industry sports an average Forward P/E of 13.91, so we one might conclude that Eli Lilly is trading at a premium comparatively.
It is also worth noting that LLY currently has a PEG ratio of 2.12. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The Large Cap Pharmaceuticals industry currently had an average PEG ratio of 2.11 as of yesterday's close.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 167, which puts it in the bottom 35% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.